At Blood Cancers Today, we like end-of-year awards as much as the next. In that spirit, we have compiled the top awards as doled out by the Twitterverse.
Top Mentions
The award for “Top Mention” goes to Chadi Nabhan, MD, MBA, FACP.
Blood Cancers Today officially launched its podcast, The HemOnc Pulse, hosted by Dr. Nabhan, who received tons of excitement and support on Twitter during the official announcement.
ANNOUNCEMENT:
Proud to bring your way during the upcoming @ASH_hematology #ASH22 a new PODCAST dedicated to all things hematology & only hematology.
Stay tuned for the #HemeOncPulse debuting Dec 2022.@SocietyofHemOnc @Blood_Cancers
Debates.
Trials.
Updates.ONLY Heme.
— chadi nabhan MD, MBA, FACP (@chadinabhan) November 12, 2022
Top Media Tweet
SOHO honors poster award winners at its Annual Meeting in Houston, Texas, in September.
SOHO Announces Poster Award Winners at 10th Annual Meeting #SOHO2022 @SocietyofHemOnc https://t.co/rj6z6kLapK pic.twitter.com/LHWL8iiAKk
— Blood Cancers Today (@Blood_Cancers) September 30, 2022
Top Media Tweet—Honorable Mention
Blood Cancers Today brings the best hem/onc content live from SOHO 2022.
We are here onsite filming at #SOHO2022. Stop by the @Blood_Cancers booth #125 to see how you can contribute! #SOHO2022. @SocietyofHemOnc pic.twitter.com/03Gu0iN49m
— Blood Cancers Today (@Blood_Cancers) September 28, 2022
Top Tweets
Mazie Tsang, MD, MAS, MS, an Assistant Professor at the Mayo Clinic in Phoenix, Arizona, shared with Blood Cancers Today her philosophy for caring about patients.
Mahalo nui loa to @MazieTsangMD
for stopping by Blood Cancers Today to share about her medical career and how her experience @uhmed taught her “to honor patients’ values, perspectives, and cultures.” https://t.co/owXmd55O03 @SocietyofHemOnc pic.twitter.com/LcgdYEoavO— Blood Cancers Today (@Blood_Cancers) October 19, 2022
Blood Cancers Today’s own Thomas Martin, MD, gets a chance to highlight a major drug approval one day after the U.S. Food and Drug Administration announcement at the SOHO Highlights State of the Art & Next Questions Meeting in October.
“Now for the 1st time I’m ever able to give this talk … we have an approved bispecific antibody and that’s teclistamab” @TomBmt133 during @SocietyofHemOnc Highlights SANQ #MM
— Blood Cancers Today (@Blood_Cancers) October 26, 2022
